Prescription Bupropion Hydrochloride Tablets Recalled for Failed Quality Specifications
Amerisource Health Services LLC is recalling 1,416 cartons of Bupropion Hydrochloride Tablets (75 mg) nationwide due to failed impurities and degradation specifications. The tablets do not meet FDA quality standards for purity.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II drug recall for failed quality specifications (impurities and degradation) with no reported illnesses or injuries. It represents a potential risk of harm from chemical impurities, matching the 'risk-of-harm products where injury has not yet been reported' criterion for Score 3 (High).
Plain-English summary
Amerisource Health Services LLC is recalling 1,416 cartons of Bupropion Hydrochloride Tablets, USP 75 mg nationwide. The product is distributed in 10 x 10 blister packs per carton, with lot number 1003837 and expiration date January 31, 2023. The recall applies to product distributed throughout the United States.
The recall was initiated because the product failed impurities and degradation specifications. The tablets do not meet FDA quality standards for chemical purity and stability.
Consumers who have this medication should consult their healthcare provider or pharmacist about whether to continue using it or obtain a replacement. Patients should not abruptly stop taking Bupropion without medical guidance.
Anyone with questions about this recall can contact their pharmacist or healthcare provider.
The recalled product
- Product
- BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
- Brand
- BUPROPION HYDROCHLORIDE
- Manufacturer
- Amerisource Health Services LLC
- Category
- Drug
- Affected units
- 1,416
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 1003837
- Exp. Date 01/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · BUPROPION HYDROCHLORIDE
- ModerateBupropion extended release tablets recalled after failing tablet specifications
FDA (Drugs) · 2025-10-29
- HighBupropion Extended-Release Tablets Recalled for Dissolution Failure
FDA (Drugs) · 2024-07-17
- HighFDA recalls Bupropion Hydrochloride tablets for foreign tablet contamination
FDA (Drugs) · 2024-01-17
- ModerateBupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-12-13
- ModerateSun Pharmaceutical Bupropion Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2023-10-25
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08